(MOLN) – PRNewswire
-
Medicxi Bolsters and Expands Team with Senior Industry Leaders
-
Allergan and Molecular Partners Present Late-Breaking Data from Phase 3 Studies of Investigational Abicipar pegol in Neovascular Wet Age-Related Macular Degeneration
-
Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-re
Back to MOLN Stock Lookup